HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 289/6/E1039    most recent 00247.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Camacho, R. C. Articles by Wasserman, D. H. Search for Related Content PubMed PubMed Citation Articles by Camacho, R. C. Articles by Wasserman, D. H.

5-Aminoimidazole-4-carboxamide-1--D-ribofuranoside renders glucose output by the liver of the dog insensitive to a pharmacological increment in insulin

Department of Molecular Physiology and Biophysics and Diabetes Research and Training Center, Vanderbilt University School of Medicine, Nashville, Tennessee

Submitted 1 June 2005 ; accepted in final form 21 July 2005

This study aimed to test whether stimulation of net hepatic glucose output (NHGO) by increased concentrations of the AMP analog, 5-aminoimidazole-4-carboxamide-1--D-ribosyl-5-monophosphate, can be suppressed by pharmacological insulin levels. Dogs had sampling (artery, portal vein, hepatic vein) and infusion (vena cava, portal vein) catheters and flow probes (hepatic artery, portal vein) implanted >16 days before study. Protocols consisted of equilibration (–130 to –30 min), basal (–30 to 0 min), and hyperinsulinemic-euglycemic (0–150 min) periods. At time (t) = 0 min, somatostatin was infused, and basal glucagon was replaced via the portal vein. Insulin was infused in the portal vein at either 2 (INS2) or 5 (INS5) mU·kg^–1·min^–1. At t = 60 min, 1 mg·kg^–1·min^–1 portal venous 5-aminoimidazole-4-carboxamide-1--D-ribofuranoside (AICAR) infusion was initiated. Arterial insulin rose 9- and 27-fold in INS2 and INS5, respectively. Glucagon, catecholamines, and cortisol did not change throughout the study. NHGO was completely suppressed before t = 60 min. Intraportal AICAR stimulated NHGO by 1.9 ± 0.5 and 2.0 ± 0.5 mg·kg^–1·min^–1 in INS2 and INS5, respectively. AICAR stimulated tracer-determined endogenous glucose production similarly in both groups. Intraportal AICAR infusion significantly increased hepatic acetyl-CoA carboxylase (ACC, Ser⁷⁹) phosphorylation in INS2. Hepatic ACC (Ser⁷⁹) phosphorylation, however, was not increased in INS5. Thus intraportal AICAR infusion renders hepatic glucose output insensitive to pharmacological insulin. The effectiveness of AICAR in countering the suppressive effect of pharmacological insulin on NHGO occurs even though AICAR-stimulated ACC phosphorylation is completely blocked.

hepatic glucose production; glycogenolysis; AMP-activated protein kinase; adenosine 5'-monophosphate; 5-aminoimidazole-4-carboxamide-1--D-ribosyl-5-monophosphate

This article has been cited by other articles:

				C. Rantzau, M. Christopher, and F. P. Alford Contrasting effects of exercise, AICAR, and increased fatty acid supply on in vivo and skeletal muscle glucose metabolism J Appl Physiol, February 1, 2008; 104(2): 363 - 370. [Abstract] [Full Text] [PDF]

				M. Christopher, C. Rantzau, Z.-P. Chen, R. Snow, B. Kemp, and F. P. Alford Impact of in vivo fatty acid oxidation blockade on glucose turnover and muscle glucose metabolism during low-dose AICAR infusion Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E1131 - E1140. [Abstract] [Full Text] [PDF]

				R. C. Camacho, E. P. Donahue, F. D. James, E. D. Berglund, and D. H. Wasserman Energy state of the liver during short-term and exhaustive exercise in C57BL/6J mice Am J Physiol Endocrinol Metab, March 1, 2006; 290(3): E405 - E408. [Abstract] [Full Text] [PDF]